[go: up one dir, main page]

PE20180555A1 - Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de metodos electroquimicos - Google Patents

Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de metodos electroquimicos

Info

Publication number
PE20180555A1
PE20180555A1 PE2018000261A PE2018000261A PE20180555A1 PE 20180555 A1 PE20180555 A1 PE 20180555A1 PE 2018000261 A PE2018000261 A PE 2018000261A PE 2018000261 A PE2018000261 A PE 2018000261A PE 20180555 A1 PE20180555 A1 PE 20180555A1
Authority
PE
Peru
Prior art keywords
naphthyridine
dihydro
dimethyl
carboxamide
metoxyphenyl
Prior art date
Application number
PE2018000261A
Other languages
English (en)
Inventor
Johannes Platzek
Kathrin Gottfried
Jens Assmann
Giulio Lolli
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20180555A1 publication Critical patent/PE20180555A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B15/00—Operating or servicing cells
    • C25B15/08—Supplying or removing reactants or electrolytes; Regeneration of electrolytes
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00—Electrolytic production of organic compounds
    • C25B3/20—Processes
    • C25B3/23—Oxidation
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00—Electrolytic production of organic compounds
    • C25B3/20—Processes
    • C25B3/25—Reduction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Electrochemistry (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a un procedimiento nuevo para la preparacion de (4S)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1 ,4-dihidro-1,6-naftiridina-3- carboxamida de la formula (1) y para la recuperacion de (48)-4-(4-ciano-2- metoxifenilo)-5-etoxi-2,8-dimetil-1 ,4-dihidro-1 ,6-naftiridina-3-carboxamida de la formula (I). a partir de (4R)-4-( 4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1 ,4-dihidro-1 ,6- naftiridina-3-carboxarnida de la formula ent-(I).
PE2018000261A 2015-08-21 2016-08-18 Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de metodos electroquimicos PE20180555A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15182040 2015-08-21
EP15182042 2015-08-21

Publications (1)

Publication Number Publication Date
PE20180555A1 true PE20180555A1 (es) 2018-04-02

Family

ID=56694167

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000261A PE20180555A1 (es) 2015-08-21 2016-08-18 Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de metodos electroquimicos

Country Status (30)

Country Link
US (1) US10392384B2 (es)
EP (1) EP3337801B1 (es)
JP (1) JP6843120B2 (es)
KR (1) KR102677034B1 (es)
CN (1) CN108137587B (es)
AU (1) AU2016311135C1 (es)
CA (1) CA2995949A1 (es)
CL (1) CL2018000426A1 (es)
CO (1) CO2018001759A2 (es)
DK (1) DK3337801T3 (es)
ES (1) ES2739907T3 (es)
HR (1) HRP20191476T1 (es)
HU (1) HUE044678T2 (es)
IL (1) IL257522B (es)
JO (1) JOP20160185B1 (es)
LT (1) LT3337801T (es)
MX (1) MX367959B (es)
NZ (1) NZ739993A (es)
PE (1) PE20180555A1 (es)
PL (1) PL3337801T3 (es)
PT (1) PT3337801T (es)
RS (1) RS59086B1 (es)
RU (1) RU2715226C2 (es)
SG (1) SG11201801378VA (es)
SI (1) SI3337801T1 (es)
TW (1) TWI725044B (es)
UA (1) UA124418C2 (es)
UY (1) UY36863A (es)
WO (1) WO2017032678A1 (es)
ZA (1) ZA201801867B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3560922A1 (de) 2018-04-24 2019-10-30 Bayer Aktiengesellschaft Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester
WO2020132716A1 (en) * 2018-12-24 2020-07-02 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Chemical compound manufacture, new salt form, and therapeutic uses thereof
CN110195239B (zh) * 2019-04-15 2020-08-14 浙江工业大学 一种多氯甲基吡啶衍生物电化学脱氯制备醛、酸的方法
CN110195238B (zh) * 2019-04-15 2020-08-14 浙江工业大学 一种三氯甲基吡啶衍生物电化学脱氯制备酰胺的方法
CN111910206B (zh) * 2019-05-07 2023-03-10 中国科学技术大学 一种合成3-氰基取代的咪唑并[1,5-a]喹啉类化合物的方法
EP3987069A4 (en) * 2019-06-21 2023-07-12 Xerion Advanced Battery Corp. PROCESS FOR EXTRACTING LITHIUM FROM SPODUMEN
CN114555599B (zh) * 2019-10-17 2024-06-07 拜耳公司 制备(4s)-(4-氰基-2-甲氧基苯基)-5-乙氧基-2,8-二甲基-1,4-二氢-1,6-萘啶-3-羧酸的酰氧基甲基酯的方法
IL292192A (en) * 2019-10-17 2022-06-01 Bayer Ag Process for the preparation of (2-cyanoethyl(4s)-4-(4-cyano-2-methoxy-phenyl)-5-hydroxy-8,2-dimethyl-4,1-dihydro-6,1-naphthyridine-3-carboxylate By separating the racemate using tartaric acid esters and diastereomers
CA3158167A1 (en) * 2019-10-17 2021-04-22 Bayer Aktiengesellschaft Photochemical process for producing (4r,4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamide
MX2022004467A (es) * 2019-10-17 2022-05-03 Bayer Ag Procedimiento para preparar (4s)-4-(4-ciano-2-metoxi-fenil)-5-etox i-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxilato de 2-cianoetilo mediante separacion de racematos utilizando esteres diastereomericos de acido tartarico.
WO2021254896A1 (en) 2020-06-16 2021-12-23 Bayer Aktiengesellschaft Process for preparing (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide enabled by a catalytic asymmetric hantzsch ester reduction
CN113214248B (zh) * 2021-04-13 2022-04-26 湖南南新制药股份有限公司 一种1,4-二氢-1,6-萘啶衍生物、药物组合物及其用途
CN113897631B (zh) * 2021-10-24 2023-05-09 昆明学院 电化学合成吡啶-2-酮衍生物的方法
CN114149427A (zh) * 2021-12-18 2022-03-08 上海鼎雅药物化学科技有限公司 非奈利酮及其中间体的合成方法
CN115340539B (zh) 2022-01-19 2024-02-27 奥锐特药业股份有限公司 制备非奈利酮及其中间体的方法
CN114605410B (zh) * 2022-04-06 2023-12-29 浙江科聚生物医药有限公司 一种非奈利酮原料药的制备方法
US20250270184A1 (en) 2022-04-18 2025-08-28 Teva Pharmaceuticals International Gmbh Processes for the preparation of finerenone
CN117304067A (zh) * 2022-06-21 2023-12-29 南京工业大学 一种非奈利酮中间体4-氰基-2-甲氧基苯甲醛的合成方法
CN115583866A (zh) * 2022-08-30 2023-01-10 上海厚博生物科技有限公司 一种用非奈利酮对映体制备非奈利酮的方法
EP4634179A1 (en) * 2022-12-16 2025-10-22 Bayer Aktiengesellschaft Sequential one-pot synthesis for preparing 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
CN119684288A (zh) * 2024-12-18 2025-03-25 安徽先和医药研究有限公司 非奈利酮的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431303A1 (de) * 1984-08-25 1986-02-27 Goedecke Ag 1,6-naphthyridin-derivate, verfahren zu deren herstellung und deren verwendung
IL75987A (en) * 1984-08-25 1991-07-18 Goedecke Ag Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
EP1902022A1 (en) 2005-07-12 2008-03-26 Glaxo Group Limited Piperazine heteroaryl derivates as gpr38 agonists
DE102006026583A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
DE102007009494A1 (de) * 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
DE102007061764A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung

Also Published As

Publication number Publication date
PL3337801T3 (pl) 2019-10-31
CA2995949A1 (en) 2017-03-02
LT3337801T (lt) 2019-08-12
CN108137587B (zh) 2020-10-23
MX2018002236A (es) 2018-03-23
SI3337801T1 (sl) 2019-08-30
WO2017032678A1 (de) 2017-03-02
MX367959B (es) 2019-09-12
RU2018109762A (ru) 2019-09-23
CL2018000426A1 (es) 2018-07-20
AU2016311135C1 (en) 2022-10-13
ZA201801867B (en) 2019-10-30
EP3337801A1 (de) 2018-06-27
IL257522A (en) 2018-04-30
US20180244668A1 (en) 2018-08-30
HK1252212A1 (zh) 2019-05-24
UA124418C2 (uk) 2021-09-15
DK3337801T3 (da) 2019-08-19
RS59086B1 (sr) 2019-09-30
RU2018109762A3 (es) 2019-12-18
CO2018001759A2 (es) 2018-02-28
TWI725044B (zh) 2021-04-21
HUE044678T2 (hu) 2019-11-28
BR112018003334A2 (pt) 2018-09-18
US10392384B2 (en) 2019-08-27
NZ739993A (en) 2022-05-27
HRP20191476T1 (hr) 2019-11-15
JOP20160185B1 (ar) 2021-08-17
JP2018523697A (ja) 2018-08-23
AU2016311135B2 (en) 2020-09-10
EP3337801B1 (de) 2019-06-12
TW201722943A (zh) 2017-07-01
SG11201801378VA (en) 2018-03-28
AU2016311135A1 (en) 2018-03-15
KR102677034B1 (ko) 2024-06-24
PT3337801T (pt) 2019-08-05
JP6843120B2 (ja) 2021-03-17
UY36863A (es) 2017-03-31
RU2715226C2 (ru) 2020-02-26
KR20180043305A (ko) 2018-04-27
CN108137587A (zh) 2018-06-08
IL257522B (en) 2020-04-30
ES2739907T3 (es) 2020-02-04

Similar Documents

Publication Publication Date Title
PE20180555A1 (es) Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de metodos electroquimicos
UY36251A (es) Procedimiento para la preparación de (4s)- 4-(4-ciano-2-metoxifenilo)-5-toxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridin-3-carbox-amida y su purificación para su uso como principio activo farmacéutico
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX367960B (es) Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenil o)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificacion para su uso como principio activo farmaceutico.
PH12016501633B1 (en) Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
EA201890256A1 (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
TN2017000196A1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
EA201790570A1 (ru) Модуляторы р2х7
BR112018009924A2 (pt) 4-((6-(2-(2,4-difluorfenil)-1,1-diflúor-2-oxoetil)piridin-3-il)óxi)benzonitrila e processos de preparação
MX2014014138A (es) Procedimiento nuevo para la preparacion de acido 2-ciclopentil-6-metoxi-isonicotinico.
UA117779C2 (uk) Піразини як модулятори gpr6
IN2014MU00675A (es)
MX2018011877A (es) Proceso mejorado para la preparacion de tartrato de butorfanol.
MX350430B (es) Proceso para preparar compuestos acido 4-amino-5-bifenil-4-il-2-hi droximetil-2-metil-pentanoico.
MX2016009325A (es) Metodo para la preparacion de 1-alquil-3-difluorometil-5-fluor-1h- pirazol-4-carbaldehidos y 1-alquil-3-difluorometil-5-fluor-1h-pira zol-4-carboxilatos.
IN2014DN10209A (es)
IN2014MU00197A (es)
MX361888B (es) Un procedimiento mejorado para producir zilpaterol.
UA74234U (uk) Спосіб одержання 1-арил-5-метил-n-r2-1h-1,2,3-триазол-4-карбоксамідів
IN2014MU00069A (es)
IN2013CH05863A (es)